Heparins for Thromboprophylaxis in COVID-19 Patients: HETHICO Study in Veneto
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 744
- 试验地点
- 1
- 主要终点
- Bleeding
研究概览
简要总结
The HETHICO study aims to collect retrospectively documented clinical information on patients hospitalized in Veneto Region (Italy) for SARS-COVID-2 infection in 2 types of settings, medical environment (COORTE MED), and intensive / sub-intensive (COORTE ICU), to assess the safety and possible efficacy of the anticoagulant treatments used for thromboprophylaxis, or in preventing thrombotic complications related to hospitalization from COVID-19.
详细描述
The HETHICO study aims to collect retrospectively documented clinical information on patients hospitalized in Veneto Region (Italy) for SARS-COVID-2 infection in 2 types of settings, medical environment (COORTE MED), and intensive / sub-intensive (COORTE ICU), to assess the safety and possible efficacy of the anticoagulant treatments used for thromboprophylaxis, or in preventing thrombotic complications related to hospitalization from COVID-19.
Furthermore, the possible association between the observed clinical evolution and the type of antithrombotic prophylaxis performed (class of drug and dose intensity) will be assessed in a large cohort of patients hospitalized in the various participating hospitals in the Veneto region and observed with follow-up. in the short term, gathering information on:
Clinical outcomes, Survival, Concomitant pathologies, Adverse events of anticoagulant drugs, Interactions with other concomitant drugs, and Risk factors.
The collected data, suitably anonymized, will be used to produce scientific works, the standardization of care paths, and the planning of targeted training events.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •proved SARS-COVID-2 infection
排除标准
- 未提供
研究组 & 干预措施
MED-Cohort
Patients hospitalized for SARS-COVID-2 infection in a medical ward
干预措施: Low Molecular Weight Heparin (Drug)
ICU-Cohort
Patients hospitalized for SARS-COVID-2 infection in a sub-intensive or intensive care unit
干预措施: Low Molecular Weight Heparin (Drug)
结局指标
主要结局
Bleeding
时间窗: 28 days
Collect and evaluate in real-life the safety data of the anti-coagulant treatments used by estimating the incidence of bleeding complications during hospitalization.
Thrombosis
时间窗: 28 days
Collect and evaluate in real-life the efficacy data of the anti-coagulant treatments used by estimating the incidence of deep vein thrombosis and/or pulmonary embolism during hospitalization.
Mortality
时间窗: 28 days
Collect and evaluate in real-life the data by estimating incidence of intra-hospital death.
次要结局
- Worsening(28 days)
- LOS(60 days)